Clinical Trial: NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

U.S., Jan. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07318636) titled 'NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC' on Dec. 16, 2025.

Brief Summary: This open-label, single-arm study is designed to evaluate the safety and preliminary efficacy of NK010 cell injection combined with a PD-1 antibody and platinum-based chemotherapy as neoadjuvant therapy in patients with resectable non-small cell lung cancer (NSCLC). The study aims to assess the safety profile, feasibility of administration, and potential antitumor activity of this combination regimen.

Study Start Date: Jan. 20

Study Type: INTERVENTIONAL

Condition: Resectable Non-...